Assessment of glucolipid metabolism, oxidation and inflammation in patients with diabetic nephropathy after probucol combined with olmesartan medoxomil therapy

摘要

Objective:To analyze the changes of glucolipid metabolism, oxidation and inflammation in patients with diabetic nephropathy after probucol combined with olmesartan medoxomil treatment.Methods:A total of 108 patients with diabetic nephropathy were randomly divided into observation group and control group (n=54), control group received olmesartan medoxomil therapy, and observation group received probucol combined with olmesartan medoxomil therapy. Differences in blood glucose and fluctuation levels, lipid metabolism indexes, oxidation/antioxidation indexes and inflammation indexes were compared between the two groups after treatment.Results:GLU, MAGE, SDBG and MPPGE levels in peripheral blood of observation group were significantly lower than those of control group; lipid indexes TC, ApoB and LDL-C content in serum were significantly lower than those of control group while ApoA1, ApoA5 and HDL-C content were significantly higher than those of control group; oxidation/antioxidation indexes AOPP, MDA and ONOO- content in serum were significantly lower than those of control group while T-AOC, SOD and GSH-PX content were significantly higher than those of control group; inflammation indexes IL-1β, IL-4, IL-18, PCT and TGF content in serum were significantly lower than those of control group.Conclusions:Probucol combined with olmesartan medoxomil therapy can optimize the overall condition in patients with diabetic nephropathy, and plays a positive role in equalizing glucolipid metabolism, inhibiting oxidation and inflammation state and other aspects.